You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Bulk Pharmaceutical API Sources for DESOGESTREL; ETHINYL ESTRADIOL


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for DESOGESTREL; ETHINYL ESTRADIOL

Vendor Vendor Homepage Vendor Sku API Url
NovoSeek ⤷  Get Started Free 62957 ⤷  Get Started Free
ABI Chem ⤷  Get Started Free AC1L1Y41 ⤷  Get Started Free
RR Scientific ⤷  Get Started Free R5217561 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Desogestrel and Ethinyl Estradiol

Last updated: July 30, 2025

Introduction

In the pharmaceutical landscape, sourcing high-quality Active Pharmaceutical Ingredients (APIs) is paramount for ensuring drug efficacy, safety, and regulatory compliance. Desogestrel and Ethinyl Estradiol, key components in combined oral contraceptives, require meticulous sourcing strategies given their widespread use and stringent regulatory standards. This report delineates the global API suppliers for these compounds, emphasizing quality assurance, manufacturing capabilities, and compliance with international standards.

Overview of Desogestrel and Ethinyl Estradiol

Desogestrel is a third-generation progestin used in hormonal contraceptives. It acts primarily by inhibiting ovulation and altering cervical mucous. Ethinyl Estradiol is a synthetic estrogen used adjunctively with progestins like desogestrel. Their combination is common in multivitamin formulations and contraceptive pills.

Both APIs are synthesized via complex chemical processes demanding high purity, potency, and consistent supply chains. Their controlled status in multiple jurisdictions necessitates suppliers to meet Good Manufacturing Practices (GMP) and adhere to pharmacopoeial standards.


Global API Manufacturing Hubs

Major API manufacturing centers exist predominantly in India, China, and Europe, with emerging suppliers in the Southeast Asian region. These regions host facilities compliant with GMP, producing high-quality APIs for global distribution.


Leading API Suppliers for Desogestrel

1. Laurus Labs (India)

Laurus Labs has established a reputable track record in synthesizing hormonal APIs, including desogestrel. Their facilities are GMP-certified, with proven capability from preclinical to commercial scale. The company emphasizes regulatory compliance aligned with US FDA, EMA, and other international standards.

2. Zhejiang Anhui Kangning Pharmacutical Co., Ltd. (China)

This Chinese manufacturer supplies desogestrel with certifications covering cGMP and ISO standards. The company invests heavily in R&D to optimize synthesis routes, ensuring high purity and yield.

3. Sun Pharmaceutical Industries Ltd. (India)

An established pharmaceutical player with integrated manufacturing, Sun Pharmaceutical produces desogestrel API meeting international quality benchmarks, catering to both domestic and export markets.

4. Hetero Labs Ltd. (India)

Hetero's API portfolio includes hormonal compounds like desogestrel. Their manufacturing processes are routinely inspected under GMP and have a track record of supply consistency.


Leading API Suppliers for Ethinyl Estradiol

1. Dr. Reddy's Laboratories (India)

A global pharmaceutical giant, Dr. Reddy's manufactures Ethinyl Estradiol adhering to stringent cGMP standards. Their API quality is validated internationally, supporting a diversified product pipeline.

2. Jiangsu Hengrui Medicine Co., Ltd. (China)

Hengrui supplies Ethinyl Estradiol that complies with USP and EP specifications. Their production facilities are certified for GMP, and they serve major clients worldwide.

3. Hetero Labs Ltd. (India)

In addition to desogestrel, Hetero produces Ethinyl Estradiol, maintaining strict quality controls and consistent supply to meet global demand.

4. Wuhan Youhua Pharmaceutical Co., Ltd. (China)

This manufacturer offers Ethinyl Estradiol with a focus on pharmaceutical-grade quality, supported by ISO and GMP certifications.


Regulatory Considerations in API Sourcing

When sourcing APIs for pharmaceutical manufacturing, regulatory approval is non-negotiable. Suppliers must demonstrate compliance with cGMP standards, provide Certificates of Analysis (CoA), and adhere to pharmacopoeial specifications (USP, EP, BP). Additionally, due diligence should include audits, supplier qualification, and ongoing batch verification to mitigate risks related to quality, supply continuity, and regulatory compliance.


Quality Assurance and Due Diligence

Procuring APIs involves rigorous quality assurance protocols:

  • Supplier Audits: Confirm GMP compliance through on-site inspections.
  • Batch Testing: Regular analysis for potency, purity, residual solvents, and impurities.
  • Documentation Review: Ensure full documentation, including process validation and stability data.
  • Supply Chain Security: Assess the supplier’s production capacity and contingency plans to prevent shortages.

Partnering with established manufacturers reduces regulatory hurdles and enhances product reliability.


Emerging Sources and Trends

With increasing regulatory scrutiny, manufacturers are focusing on ensuring API traceability and transparency. Companies are adopting serialization and blockchain for supply chain integrity. Additionally, some emerging suppliers leverage green chemistry and sustainable practices to meet environmental regulations and corporate responsibility standards.


Conclusion

Securing reliable sources for desogestrel and ethinyl estradiol APIs requires a thorough understanding of global manufacturing capabilities, regulatory environments, and quality assurance protocols. India and China dominate the API supply landscape, offering high-quality, cost-effective options. However, due diligence remains essential to ensure compliance, prevent supply disruptions, and maintain product integrity.


Key Takeaways

  • Focus on established GMP-certified suppliers with proven regulatory compliance.
  • Prioritize suppliers with comprehensive documentation, batch consistency, and quality control measures.
  • Regularly audit and verify supplier capabilities to mitigate supply chain risks.
  • Recognize emerging trends emphasizing transparency, sustainability, and traceability.
  • Maintain updated knowledge of regulatory requirements across different markets for seamless approval processes.

FAQs

1. How can I verify the GMP compliance of an API supplier?
Conduct on-site audits, review third-party inspection reports, and request certification documents such as ISO and GMP certificates. Regulatory inspections by agencies like the US FDA or EMA further validate compliance.

2. What are the critical quality parameters for desogestrel and ethinyl estradiol APIs?
Purity (>99%), potency, residual solvents, heavy metals, and specific impurities are key parameters. Certificates of Analysis should confirm conformity with pharmacopoeial standards.

3. Are there regulatory restrictions on sourcing APIs from China and India?
While historically scrutinized, many suppliers from these countries now meet international standards. Due diligence, including supplier qualification and batch validation, is essential to mitigate compliance risks.

4. How does the supply chain impact API sourcing decisions?
A resilient supply chain with multiple qualified suppliers reduces risks related to shortages and delays. Long-term relationships and local regulations also influence sourcing choices.

5. What are emerging trends in API sourcing for hormonal compounds?
Increased emphasis on sustainability, quality transparency, advanced traceability, and digital supply chain solutions are shaping current sourcing strategies.


References:
[1] Pharmacompass, "Top Desogestrel API Manufacturers," 2023.
[2] International Pharmacopoeia, "Standards for Ethinyl Estradiol," 2022.
[3] US FDA, "Good Manufacturing Practices for APIs," 2021.
[4] European Pharmacopoeia, "API Quality Standards," 2022.
[5] Industry Reports, "Global API Market Overview," 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.